|
ZURICH, Switzerland – Nobel Biocare welcomes today's decision of the MPA to continue the sales of NobelDirect and NobelPerfect one-piece implants. The Company is satisfied that the Agency did not find a reason to prohibit the continued release of those actual implants to the market.
The Company is also gratified that several of the actions required by the MPA in order to further minimize risk were proposed by Nobel Biocare in its letter dated 13 October 2006. Nobel Biocare will fully cooperate with the MPA and report to the Agency as requested. Nobel Biocare will not make any further comments on the decision of the MPA. Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands Brånemark System®, NobelSpeedyT, NobelReplaceT, NobelPerfect®, NobelDirect®, Replace® Select, (dental implants) and Procera® (individualized dental prosthetics). Nobel Biocare is a one-stop shop for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education and clinically documented treatment concepts. Nobel Biocare has over 1,900 employees and recorded revenue of EUR 485 million in 2005. The Company is domiciled in Zurich, Switzerland with headquarters in Zurich and in Gothenburg, Sweden. Production takes place at four production sites located in Sweden and the USA. Nobel Biocare has direct sales organizations in 34 countries. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange and on the Stockholm Stock Exchange, Sweden. SOURCE: Nobel Biocare Holding AG
Email to a friend  | Print this article 
|
Idiomas
